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Abstract
Objective: The specific inhibition of phosphodiesterase (PDE)4 and dual inhibition of PDE3 and PDE4 has been shown to
decrease inflammation by suppression of pro-inflammatory cytokine synthesis. We examined the effect of roflumilast, a
selective PDE4 inhibitor marketed for severe COPD, and the investigational compound pumafentrine, a dual PDE3/PDE4
inhibitor, in the preventive dextran sodium sulfate (DSS)-induced colitis model.
Methods: The clinical score, colon length, histologic score and colon cytokine production from mice with DSS-induced
colitis (3.5% DSS in drinking water for 11 days) receiving either roflumilast (1 or 5 mg/kg body weight/d p.o.) or
pumafentrine (1.5 or 5 mg/kg/d p.o.) were determined and compared to vehicle treated control mice. In the pumafentrine-
treated animals, splenocytes were analyzed for interferon-c (IFNc) production and CD69 expression.
Results: Roflumilast treatment resulted in dose-dependent improvements of clinical score (weight loss, stool consistency
and bleeding), colon length, and local tumor necrosis factor-a (TNFa) production in the colonic tissue. These findings,
however, were not associated with an improvement of the histologic score. Administration of pumafentrine at 5 mg/kg/d
alleviated the clinical score, the colon length shortening, and local TNFa production. In vitro stimulated splenocytes after
in vivo treatment with pumafentrine showed a significantly lower state of activation and production of IFNc compared to
no treatment in vivo.
Conclusions: These series of experiments document the ameliorating effect of roflumilast and pumafentrine on the clinical
score and TNF expression of experimental colitis in mice.
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Introduction
Inflammatory bowel disease (IBD) is characterized by a
disturbed balance of pro- and anti-inflammatory cytokines. Tumor
necrosis factor-a (TNFa), which is elevated in the intestinal
mucosa of both of its entities – Crohn’s disease (CD) and ulcerative
colitis (UC) [1] plays a crucial role in the pathogenesis of IBD [2],
a fact further underlined by the efficacious treatment of patients
with CD and UC with anti-TNFa antibodies [3,4,5]. However,
repeated administration of infliximab results in the production of
auto-antibodies and antibodies against double-stranded DNA
[3,4]. In addition, patients treated with infliximab are at an
increased risk of concomitant infectious complications secondary
to the sustained immune suppression [6].
Among the agents known to inhibit pro-inflammatory cytokine
production rather than to block its biological function are cyclic
adenosine-39,59-monophosphate (cAMP)-elevating PDE inhibi-
tors. A major PDE isoenzyme family in mononuclear inflamma-
tory cells, the main source of TNFa production, is PDE4 [7]. The
specific inhibition of PDE4 with rolipram is 500-fold more potent
in suppressing TNFa synthesis in human mononuclear cells
compared to pentoxifylline [8]. PDE4 inhibitors have shown
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efficacy in the treatment of several chronic inflammatory
disorders, including experimental colitis [9,10,11]. Unfortunately,
the clinical use of rolipram and other investigational PDE4
inhibitors was limited by its adverse effects profile [7,12]. Another
major PDE isoenzyme found in several human immune and
inflammatory cells (T-cells, macrophages, dendritic cells) is PDE3
[13]. Interestingly, dual selective inhibition of PDE3 and PDE4
frequently leads to an over additive modulation of inflammatory
cell functions compared to inhibition of either isoform alone
[14,15].
Roflumilast is an oral, once daily, PDE4 inhibitor marketed in
the European Union and United States and several other countries
for the treatment of severe COPD [15,16,17,18]. In vitro, in vivo
and clinical studies demonstrated an anti-inflammatory potential
of roflumilast accompanied by a favorable tolerability profile
compared to earlier PDE4 inhibitors [15,16,19,20]. These anti-
inflammatory effects of the PDE4 inhibitor may translate into the
improved lung function and reduced rate of exacerbations in
patients with moderate to severe COPD as recently documented
in large-scale clinical trials. Roflumilast was generally well
tolerated [17,18,21].
In the present study we investigated the effect of the PDE4
inhibitor roflumilast and the PDE3/4 inhibitor pumafentrine [22]
in the preventive model of murine dextran sulphate sodium (DSS)-
induced colitis [23]. DSS-induced colitis is the most frequently
used model for IBD and is responsive to and predictive of drugs
used for the treatment of IBD.
Materials and Methods
Mice
Female, 8-week old BALB/c mice (Harlan Winkelmann,
Borchen, Germany) weighing 20 to 22 g were used in this study.
The animals were housed in rooms at a controlled temperature
and with light/dark (12h/12h) cycles. They were fed standard
mice chow pellets and had access to tap water supplied in bottles.
Mice were euthanized by cervical dislocation under isoflurane
anesthesia (Forene; Abbott GmbH, Wiesbaden, Germany).
Animal handling, clinical as well as histologic scoring of colitis
were performed as treatment-blinded assessments. All experiments
were approved by the regional animal study committee of the
Ludwig-Maximilians University of Munich and were in agreement
with the guidelines for the proper use of animals in biomedical
research. All efforts were made to minimize suffering.
Reagents
Roflumilast (3-cyclopropylmethoxy-4-difluoromethoxy-N-hel-
lo3,5-di-chloropyrid-4-yl]-benzamide) and pumafentrine ((-)-cis-9-
ethoxy-6-(4-diisopropylaminocarbonyl-phenyl)-8-methoxy-2-
methyl-1,2,3,4,4a,10b-hexahydro-benzohelloc]hello1,6]naphthyri-
dine-hydrochloride) were synthesized by the Department of
Chemistry at the Nycomed GmbH, Konstanz, Germany, a
member of the Takeda Group. The compounds were suspended
in 4% methylhydroxylpropylcellulose with PEG400 (methocel;
Dow Chemicals, Midland, USA) diluted in distilled water to final
concentrations for oral dosing of 1 mg/kg/d or 5 mg/kg/d body
weight for roflumilast and 1.5 mg/kg/d or 5 mg/kg/d for
pumafentrine.
Induction of Colitis and Treatment
Mice were fed 3.5% DSS (molecular weight 30–40 kDa; ICN,
Eschwege, Germany) dissolved in sterile, distilled water ad libitum
throughout the experimental period (days 1–11). The DSS
concentration was determined in previous dose finding studies
for Balb/c mice [24]. The animals within each group showed a
comparable severity of colitis and the amount of consumed
drinking water per animal was similar in all experimental groups –
independently of treatment. Roflumilast, pumafentrine, and 4%
methocel (vehicle) were freshly prepared and administered orally
(by gavage) once daily in a volume of 200 ml in parallel with DSS-
feeding. Control mice had free access to tap water. They once
daily received oral roflumilast, pumafentrine, or 4% methocel for a
total of 11 days. The pharmacological doses were selected based
on previous in vivo experiments [22,25].
Determination of Clinical Score, Colon Length and
Histologic Score
Body weights, as well as stool consistency and occult blood or
the presence of gross blood per rectum were determined daily.
Two investigators blinded to the protocol independently assessed
the clinical score as previously described [9,10,24]. Briefly, weight
loss of 1–5%, 5–10%, 10–20%, and .20% was scored as 1, 2, 3,
and 4, respectively. For stool consistency, 0 was scored for well-
formed pellets, 2 for pasty and semiformed stools, which did not
stick to the anus, and 4 for liquid stools that remained adhesive to
the anus. Bleeding was scored 0 for no blood in hemoccult, 2 for
positive hemoccult, and 4 for gross bleeding from the rectum.
Weight, stool consistency, and bleeding sub-scores were added and
divided by 3, resulting in a total clinical score ranging from 0
(healthy) to 4 (maximal activity of colitis). Post mortem the entire
colon (cecum to anus) was removed from the caecum to the anus
and the colon length was measured as an indirect marker of
inflammation. Rings of the transverse part of the colon were fixed
in 10% formalin and embedded in paraffin for histologic analysis.
Sections (4 mm) were stained with hematoxylin & eosin. Histologic
scoring was performed based on the extent of infiltration of
inflammatory cells: 0 for very few inflammatory cells in the lamina
propria; 1 for increased numbers of inflammatory cells, including
neutrophils in the lamina propria; 2 for confluence of inflamma-
tory cells, extending into the submucosa; and 3 for extension
through deeper structures of the bowel wall. In addition tissue
damage was assessed and scored from 0 (no tissue damage) to 3
(most severe tissue damage). The two sub-scores for inflammation
and tissue damage were added and the combined histologic score
ranged from 0 (no changes) to 6 (extensive cell infiltration and
tissue damage).
Colon TNFa Extraction
Strips (about 4 cm) of colon from DSS-exposed and from non-
DSS exposed mice with and without roflumilast or pumafentrine
treatment were weighed, vigorously vortexed for 1 min in 100 ml
of PBS (Roche, Ingelheim, Germany) and centrifuged at 10.000x
at 4uC for 15 min. The supernatants (eluates) were stored at –
70uC until further use.
Cytokine Detection
TNFa in the colonic supernatants and IFNc in the medium of
cell cultures were quantified with a commercial enzyme-linked
immunosorbent assay kit (Endogen, Woburn, USA) according to
the manufacturer’s instructions. The lower limit of detection of
both assays was 50 pg/ml.
Cell Culture and Flow Cytometry
Spleens were aseptically removed from pumafentrine-treated
mice at day 11 and weighed. Cell suspensions were prepared
according to standard procedures [26]. Cells were washed twice in
RPMI-1640, resuspended in medium containing 10% fetal calf
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serum, and cultured at a concentration of 2.56106 cells/ml in 48-
well plates. Cultures were incubated for 20 h in the presence or
absence of phorbol myristate acetate (PMA, 25 ng/ml, Sigma,
Munich, Germany) plus ionomycin (500 ng/ml, Sigma) at 37uC in
a humidified atmosphere with 5% CO2. At the end of the
incubation period half of the culture medium and cells were frozen
at –70uC until cytokine measurement. The remaining cultures
were used for flow cytometry analysis (FACS Calibur; Becton
Dickinson, Heidelberg, Germany). Flow cytometry followed
routine procedures using 56106 splenocytes/sample. To deter-
mine the expression of CD69, CD45R, CD3 and Mac, cells were
labeled with either fluorescein isothiocyanate- or phycoerythrine-
labeled specific antibodies (Becton Dickinson).
Statistical Analysis
Biostatistical analysis of the data was performed on the basis of
means. Monotone dose dependency for the inhibition of the
clinical score was evaluated by the nonparametric Jonckheere
Terpstra test using the individual data at each investigated time
point. This test is similar to the Kruskal-Wallis test in that the null
hypothesis is that several independent samples are from the same
population. However with the Kruskal-Wallis test there is no a
priori ordering of the populations from which the samples are
drawn. The Jonckheere Terpstra test has more statistical power
than the Kruskal-Wallis test when there is a-priori ordering and
therefore has been used for this study. All other parameters (colon
length, histologic score, cytokine concentration in colonic tissue,
cytokine production, or CD69 expression by spleen cells) were
tested also by the Jonckheere Terpstra test at a given time point
after sacrifice with a a level of 0.05. Data are presented as mean
+/2 SEM.
Results
Roflumilast Mitigates Experimental Colitis in Mice
Clinical score and colon length. Mice exposed to 3.5%
DSS developed signs of colitis as expressed by a clinical score
higher than 0.5 starting on day 2 (Figure 1A). Treatment with
5 mg/kg/d roflumilast halted the progression of colitis as
expressed by a lower clinical score versus the roflumilast 1 mg/
kg/d group and the control group, respectively, starting from day
10. The difference persisted illustrating no further progression of
colitis at the point of the last measure on day 11 for the roflumilast
5 mg/kg/d group (p,0.01). On day 11, the difference was also
significant for the roflumilast 1 mg/kg/d group (p,0.05; n= 8 per
group; Figure 1A). In the animals exposed to DSS, each of the
three clinical parameters was independently improved by admin-
istration of 5 mg/kg/d roflumilast (data not shown). Mice not
exposed to DSS and treated with either 5 mg/kg/d roflumilast or
4% methocel did not show any signs of colitis (n = 5).
Colon length is an indirect and reproducible morphologic
parameter for the severity of colonic inflammation (Siegmund
et al. 2001; Loher et al. 2003). Roflumilast partially and dose-
dependently reversed the DSS-induced about 40% reduction in
colon length by 31% (p,0.01) and 58% p,0.001) at 1 and 5 mg/
kg/d dose levels, respectively (n = 8 each group). The control
groups not exposed to DSS and treated with 5 mg/kg/d
roflumilast or 4% methocel showed the greatest colon length
(n = 5), respectively (Figure 1B).
Histologic score. Histology of rings of the transverse part of
the colon in DSS-exposed mice revealed multiple erosive lesions
and inflammatory cell infiltration composed of mainly macro-
phages with fewer lymphocytes and occasional eosinophils and
neutrophils (Figure 2A). After 11 days of continuous DSS
administration, treatment with roflumilast showed a tendency to
decrease the histologic score as compared to the DSS control
group (Figure 2B). In the control groups not exposed to DSS, no
histologic signs of inflammation were detected.
TNFa concentration in colonic tissue. TNFa concentra-
tion in the colonic tissue was reduced in roflumilast (5 mg/kg/d)-
treated DSS-mice on day 11 compared to the 4% methocel-
treated DSS group (Figure 3; n = 5). Colons of control mice not
being exposed to DSS but receiving roflumilast showed mean
TNFa concentrations comparable to the DSS/roflumilast group
(Figure 3). Preliminary experiments showed that the colonic
TNFa concentration in control animals receiving regular water
was not different if PDE4 was inhibited or not (data not shown).
Pumafentrine Alleviates Experimental Colitis in Mice
The therapeutic potential of the PDE4 inhibitor roflumilast in
DSS-induced colitis led us to evaluate the effect of a dual selective
PDE3/PDE4-inhibition with pumafentrine in this model.
Clinical score and colon length. Mice exposed to 3.5%
DSS developed signs of colitis as expressed by a clinical score of
greater than 0.5 from day 4 onward (Figure 4A). Oral
administration of pumafentrine 5 mg/kg/d retarded the onset of
colitis to day 6. No dose dependency of the treatment was noted
starting day 8. Treatment with pumafentrine 5 mg/kg/d resulted
in a lower clinical score starting at day 6 of the experiment and
lasting until the end of the experiment on day 11 (n= 16;
Figure 4A). Administration of 1.5 mg/kg/d pumafentrine did not
delay the onset of clinical signs of colitis and also did not influence
the clinical score until day 11 when compared to the untreated
DSS animals. The non-DSS control animals, which received
regular drinking water and pumafentrine 5 mg/kg/d, 20 mg/kg/
d, or 4% methocel (n = 8) did not develop signs of colitis during the
experimental course (all clinical scores ,0.5 on days 1 to 11).
Colon length, a surrogate for colitis severity, was significantly
longer in the 5 mg/kg/d pumafentrine group as compared to the
control group. This represents a 36% reversal by pumafentrine of
a 37% shortening in the DSS group. DSS-exposed animals treated
with 1.5 mg/kg/d pumafentrine did not show any significant
difference compared to animals treated with DSS only. In the
control groups, the highest colon length was observed (Figure 4B).
Histologic score. Histologic analysis of the rings of the
transverse part of the colon in DSS-fed mice revealed multiple
erosive lesions and inflammatory cell infiltrations. After 11 days of
continuous DSS administration, treatment with 5 mg/kg/d
pumafentrine showed a tendency to decrease the histologic score
compared to the 4% methocel-treated group, an effect that did not
reach statistical significance (Figure 4C). In non-DSS control
animals, no signs of inflammation could be detected. Animals
treated with pumafentrine 20 mg/kg/d as well as those receiving
methocel had similarly low scores.
TNFa concentration in colonic tissue. For measurement of
colonic tissue TNFa concentrations the colons of mice treated as
described above were obtained at day 11. The TNFa concentra-
tion in the colonic tissue was reduced in pumafentrine-treated
DSS-mice compared to the methocel group at day 11 (Figure 5).
Colons displaying no signs of inflammation in the pumafentrine
control groups showed low mean TNFa concentrations
(Figure 5).
IFNc production by cultured splenocytes. As dual selec-
tive PDE3/PDE4 inhibitors have never been tested in a preventive
colitis model we evaluated the effects of in vivo-administered
pumafentrine on IFN-c production in vitro. Splenocytes at the end
of day 11 were cultured for 20 h with PMA (25 ng/ml) plus
ionomycine (500 ng/ml) or without stimulus. PMA plus ionomy-
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cine stimulated splenocytes from the methocel-treated DSS group
showed a higher IFNc production as compared to the pumafen-
trine-treated animals (Figure 6A). Controls not exposed to DSS
showed the highest IFNc secretion (20 mg/kg/d pumafentrine
group). In preliminary experiments no significant difference in
IFNc production between control animals receiving pumafentrine
Figure 1. Effect of roflumilast on clinical score and colon length. A. Mitigation of DSS-induced colitis by roflumilast. Mice were
exposed to 3.5% DSS in drinking water for 11 days. Either 1 mg/kg/d roflumilast, 5 mg/kg/d roflumilast or 4% methocel were administered orally
once daily for 11 days (n = 8). Non-DSS-treated mice received 5 mg/kg/d roflumilast (n = 8) or 4% methocel (n = 5). The degree of colitis was
quantified by the clinical score assessing weight loss, stool consistency and rectal bleeding (range from 0= healthy to 4 = maximal disease activity).
Scores are depicted as mean 6 SEM; *p,0.05, **p,0.01 versus DSS+methocel. B. Effect of roflumilast on colon length shortening in DSS-
induced colitis. Mice were exposed to 3.5% DSS in drinking water for an 11 day period. Roflumilast treatment (either 1 mg/kg/d or 5 mg/kg/d
orally, once daily for eleven days) or 4% methocel were started on the same day as DSS administration (n = 8). Non-DSS mice received 5 mg/kg/d
roflumilast (n = 8) or 4% methocel (n = 5). Values are depicted as mean 6 SEM. **p,0.01, ***p,0.001 versus DSS+methocel.
doi:10.1371/journal.pone.0056867.g001
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or water was detected. The unstimulated splenocytes did not
produce detectable levels of IFNc (data not shown).
CD69 expression by cultured splenocytes. Splenocytes
were also examined by flow cytometry (Figure 6B) for expression
of CD69, an activation marker for a wide variety of immune cells.
The investigated splenocyte cell population consisted of 50%
lymphocytes (CD45R+), 32% T-cells (CD3+), 7% macrophages
(Mac-1+) and 11% cells of unknown specificity (data not shown).
Within the DSS exposed group and after stimulation with PMA
plus ionomycin for 20 h the splenocytes from animals receiving
methocel showed increased expression of CD69 compared with
cells derived from animals receiving pumafentrine. In animals not
exposed to DSS and treated with 20 mg/kg/d pumafentrine
values of CD69 expression were comparable to the DSS methocel
group (Figure 6B). Less than 6% of unstimulated splenocytes
were positive for CD69 independent of the various treatments.
There was no significant difference in CD69 expression on
Figure 2. Effect on histologic signs of colonic inflammation by roflumilast. Mice were exposed to 3.5% DSS in drinking water for 11 days
and were treated with roflumilast (either 1 or 5 mg/kg/d orally once daily for 11 days, n = 8) or 4% methocel (n = 5). Non-DSS mice received 5 mg/kg/
d roflumilast (n = 8) or 4% methocel (n = 5). At day 11 mice were euthanized, colon rings were stained and the histologic score (degree of
inflammation and tissue damage: 0 = no changes to 6 = extensive cell infiltration and tissue damage) was determined in a blinded fashion as
described in the Materials and Methods. A. Representative cross sections of the transversing colon. Magnification of the images is 200-fold. B. Scores
are depicted as means 6 SEM.
doi:10.1371/journal.pone.0056867.g002
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splenocytes in the control groups between the pumafentrine and
4% methocel control animals.
The relative improvement for the endpoints used after
treatment with both substances is summarized in Table 1.
Discussion
In the present study, we demonstrated the in vivo effects of once
daily oral administration of the PDE4 inhibitor roflumilast and the
PDE3/PDE4 inhibitor pumafentrine in the prevention of DSS-
induced colitis. Treatment with roflumilast dose-dependently
ameliorated the clinical score, led to a reduced shortening of the
colon length and decreased concentration of TNFa in colonic
tissue. However, this improvement was not associated with a lower
histologic score. Pumafentrine at a dose of 5 mg/kg/d reduced the
clinical score and partially reversed colon shortening and TNFa
synthesis in colonic tissue. There was a tendency to improve the
histopathological colonic changes. As a systemic effect of in vivo
treatment with pumafentrine, isolated splenocytes ex vivo synthe-
sized less IFNc and expressed lower amounts of CD69 on the cell
surface after stimulation with PMA and ionomycine than
splenocytes derived from control animals.
In the testing of novel therapeutics the DSS-induced colitis
model, used in the current study, has a number of advantages,
including its simplicity and the high degree of uniformity and
reproducibility of the colonic lesions [23]. The cytokine profile and
histopathology of murine DSS-colitis has similarities with both
forms of IBD, namely elevation of pro-inflammatory cytokines,
such as TNFa and IFNc, transmural inflammation, and aphthous
erosions (like CD) as well as increased levels of IL-4 and crypt
abscesses (like UC). The DSS model of murine colitis has been
proven useful for preclinical testing of new compounds for the
therapy of human IBD [23,27,28,29].
Among the PDE isoforms PDE3 and PDE4 were identified as
the predominant cAMP-hydrolyzing PDE in human inflammatory
cells. Elevation of intracellular cAMP by inhibition of PDE4 is
associated with a broad anti-inflammatory activity in vitro,
including suppression of TNFa and IFNc, and induction of IL-
10 [7,11,15]. A combined inhibition of PDE3 and PDE4 may
result in overadditive effects on anti-inflammatory cellular
functions [15].
Early PDE4 inhibitors have successfully been tested in animal
models of experimental arthritis, autoimmune encephalomyelitis,
and respiratory inflammatory diseases, where PDE4 inhibitors
resulted in reduced inflammatory cell infiltrates and expression of
pro-inflammatory cytokines [13,30,31]. In humans, however, the
clinical use of early PDE4 inhibitors was limited by their
tolerability profile. Roflumilast showed anti-inflammatory activity
in animal models and in humans, was more potent than the early
PDE4 inhibitors rolipram and cilomilast [16,25], but was well
tolerated [21].
By combining PDE3 and PDE4 inhibitors in vivo the benefits of
over-additive effects may apply as described in vitro. Dual selective
inhibitors of PDE3 and PDE4 have been studied in animal models
of asthma (benafentrine and zardaverine) [32] or experimental
pulmonary hypertension (pumafentrine) [22].
Recent data from the literature suggest that inhibition of PDE4
might provide a novel approach in the therapy of IBD in humans.
The PDE4 inhibitors rolipram, mesopram and tetomilast
improved DSS-colitis in a preventive, therapeutic and chronic
setting [9,10,33,34]. Rolipram had a stronger anti-inflammatory
activity compared to pentoxyphylline in the acute DSS-colitis
model [35]. In humans the oral once daily administration of
tetomilast (OPC-6535) has been tested for mild to moderately
active UC in a randomized controlled trial. While a post hoc
analysis suggested efficacy of tetomilast in UC patients with high
disease activity, the primary end point (improvement of clinical
disease activity) did not reach statistical significance [36].
In our study, we focused the investigations of the selective PDE4
inhibitor roflumilast and the dual-selective PDE3/4 inhibitor
pumafentrine on two endpoints. First, local effects at the sites of
inflammation were examined. There, the clinical activity was
Figure 3. Reduction of colonic mucosa TNFa content by roflumilast. Mice were exposed to 3.5% DSS in drinking water for eleven days and
were treated with roflumilast (either 1 or 5 mg/kg/d orally once daily for 11 days, n = 8) or 4% methocel (n = 5). At day 11 the colon was removed,
weighed, vortexed in PBS and centrifuged. TNFa was quantified in the eluate by ELISA. Values represent mean 6 SEM; *p,0.05.
doi:10.1371/journal.pone.0056867.g003
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determined with a semiquantitative scoring system that has been
described as a reliable marker of pathologic changes during the
disease course [9,10,24,37]. Roflumilast dose-dependently allevi-
ated the clinical course of colitis. Pumafentrine improved the
clinical score at the dose of 5 mg/kg/d. Comparable results were
seen in the shortening of the colon as a morphometric surrogate
for the degree of inflammation. TNFa is a key cytokine in human
IBD. The local TNFa expression was measured ex vivo as described
previously [10,24]. Roflumilast and pumafentrine both signifi-
cantly reduced the synthesis of TNFa in the colon. However this
suppression was stronger in the pumafentrine (54%) versus
roflumilast (27%) treated animals. These observations may further
support that TNFa is only one example for cytokines being
involved in this experimental model of colitis, amongst other
inflammatory mediators possibly modulated by the PDE inhibitor
(e.g. IL-2, IL-10 or IFNc). Further studies should address this
hypothesis, by testing the involvement of additional cytokines in
this model. Surprisingly, no significant change on the histologic
score was observed with both substances. This was not in
concordance with previous reports, which showed a close relation
between crypt lesions and clinical activity [37]. This could be
explained by the high degree of inflammation in all DSS-exposed
animals in this experimental series. An alternate explanation could
be an insufficient efficacy of the tested substances in experimental
colitis. While surrogate parameters of inflammation were reduced,
this improvement was not reflected by the histologic score,
suggesting that additional factors, aside a reduction in TNFa levels
could be responsible for the observed tissue damage.
As PDE3/PDE4 inhibitors have not previously been tested in a
preventive colitis model we examined the systemic effect of
pumafentrine by investigation of splenocyte phenotype and
function. As endpoints of these experiments IFNc, a cytokine
released upon natural killer cell and T-cell activation, and CD69,
one of the earliest cell surface antigens induced on activated T
cells, thymocytes, B cells, natural killer cells, and neutrophils were
chosen [38]. Both IFNc synthesis and expression of CD69 were
markedly suppressed in the pumafentrine group compared to the
group exposed to DSS only. This finding was consistent with the
reduced clinical score, the shortening of the colon length, and
TNFa expression in the colon. No inhibitory effect on IFNc
Figure 4. Effect of pumafentrine on clinical score, colon length and histologic score. A. Efficacy of pumafentrine in DSS-induced
colitis. Mice were exposed to 3.5% DSS in drinking water for eleven days. Either 1.5 mg/kg/d pumafentrine (n = 8), 5 mg/kg/d pumafentrine (n = 16)
or 4% methocel (n = 16) were administered orally once daily for eleven days. Non-DSS mice received either 20 mg/kg/d pumafentrine or 4% methocel
(n = 8). The degree of colitis was quantified by the clinical score assessing weight loss, stool consistency and rectal bleeding (range from 0= healthy
to 4 = maximal disease activity). The scores are depicted as mean 6 SEM; *p,0.05, **p,0.01 versus DSS+methocel. B. Reduction of colon length
shortening in DSS-induced colitis by pumafentrine. Mice were exposed to 3.5% DSS in drinking water for an eleven day period. Pumafentrine
treatment (either 1.5 mg/kg/d (n = 8) or 5 mg/kg/d (n = 16) orally, once daily for 11 days) or 4% methocel (n = 12) were started the same day as DSS
administration. Non-DSS mice received 20 mg/kg/d pumafentrine or 4% methocel (n = 8), respectively. Values are depicted as mean6 SEM. **p,0.01
versus DSS+methocel. C. Effect on histologic signs of colonic inflammation by pumafentrine. Mice were exposed to 3.5% DSS in drinking
water for eleven days and were treated with pumafentrine (either 1.5 mg/kg/d (n = 8) or 5 mg/kg/d (n = 16) orally once daily for 11 days) or 4%
methocel (n = 12). Non-DSS mice received 20 mg/kg/d pumafentrine or 4% methocel (n = 8). At day 11 mice were euthanized, colon rings were
stained and the histologic score (degree of inflammation: 0 = no changes to 6 = extensive cell infiltration and tissue damage) was determined in a
blinded fashion as described in detail in the Material and Methods. Scores are depicted as means 6 SEM.
doi:10.1371/journal.pone.0056867.g004
Figure 5. Effect of pumafentrine on colonic mucosa TNFa concentration. Mice were exposed to 3.5% DSS in drinking water for 11 days and
were treated with pumafentrine (either 1.5 mg/kg/d (n = 8) or 5 mg/kg/d (n = 16) orally once daily for 11 days) or 4% methocel (n = 12). Non-DSS mice
received 20 mg/kg/d pumafentrine or 4% methocel (n = 8). At day 11, the end of experiment, the colon was removed, weighed, vortexed in PBS and
centrifuged. TNFa was quantified in the eluate by ELISA. Values represent mean 6 SEM; *p,0.05 versus DSS+methocel.
doi:10.1371/journal.pone.0056867.g005
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Figure 6. Systemic effects of pumafentrine. A Effect of in vivo administered pumafentrine on PMA/ionomycine-induced IFNc
synthesis by splenocytes from DSS-exposed mice. Mice were exposed to 3.5% DSS in drinking water for 11 days and were treated with
pumafentrine 5 mg/kg/d (n = 8) orally once daily for 11 days) or 4% methocel (n = 8). Non-DSS mice received 20 mg/kg/d pumafentrine (n = 8). After
day 11 spleens were removed aseptically and splenocytes were isolated. After a 20 h incubation period with PMA 25 ng/ml and ionomycine 500 ng/
ml, the experiment was stopped by three freeze-thaw cycles and total IFNc was measured by ELISA. Results are depicted as mean 6 SEM. *p,0.05
versus DSS+methocel. B. Effect of in vivo administered pumafentrine on PMA/ionomycine-induced CD69 expression by splenocytes
from DSS-exposed mice. Mice were exposed to 3.5% DSS in drinking water for 11 days and were treated with pumafentrine 5 mg/kg/d (n = 8)
orally once daily for 11 days) or 4% methocel (n = 8). Non-DSS mice received 20 mg/kg/d pumafentrine (n = 8). After day 11 spleens were removed
aseptically and splenocytes were isolated and stimulated with PMA 25 ng/ml and ionomycine 500 ng/ml. After 20 h incubation period the CD69-
expression was determined by flow cytometry. Bars represent the mean 6 SEM of CD69 positive splenocytes. *p,0.05 versus DSS+methocel.
doi:10.1371/journal.pone.0056867.g006
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synthesis or CD69 expression by pumafentrine treatment was
detected in mice not exposed to DSS (data not shown).
These data indicate that elevation of intracellular cAMP
influences the regulation of IFNc and CD69. Nonetheless, these
results cannot be explained by a direct influence of pumafentrine
as ex vivo all pharmacologic substances were washed out during the
isolation process. It is known that activation of adenylate cyclase
by autocrine mediators such as prostaglandin E2 (PGE2) or
prostacyclin may have a synergistic effect with PDE inhibition to
augment cAMP and reduce inflammatory cellular effects [39]. In
the inflamed mucosa of IBD patients, PGE2 and prostacyclin
concentrations are elevated. Therefore, oral administration of
specific PDE inhibitors might lead to the strongest effect locally in
the gut. IFNc synthesis was higher in stimulated splenocytes of
mice not exposed to DSS as compared to DSS-exposed mice. This
might be due to a desensitization of splenocytes during the
systemic inflammatory response, as described for LPS-induced
desensitization in murine monocytes [40]. In addition, due to the
absence of inflammatory mediators such as PGE2 and prostacy-
clin, pumafentrine might not have been able to exert its synergistic
effects leading to a preservation of the IFNc producing cell pool. A
similar phenomenon was seen by treatment with the adenosine
kinase inhibitor GP515 (also an cAMP-elevating agent, [24]) and
the PDE4 inhibitor mesopram (data not shown). The lack of
efficacy observed for the 1.5 mg/kg/d pumafentrine group was
probably due to the low dose.
Conclusions
This study demonstrated, that the PDE4 inhibitor roflumilast
and the PDE3/PDE4 inhibitor pumafentrine dose-dependently
ameliorated the clinical score and colonic TNFa production in
murine DSS-induced colitis in a preventive setting, while not
affecting the histopathologic colonic findings. Roflumilast has been
investigated in largescale clinical studies in patients with COPD,
showing anti-inflammatory activity leading to a reduction of
COPD exacerbations and improvement of the FEV1 with
acceptable tolerability. PDE4 or PDE3/4 inhibitors might
represent potential tools for the anti-inflammatory therapy of
IBD. Future studies should address additional mechanisms of
action of these PDE inhibitors, focussing on their anti-inflamma-
tory or cytoprotective activity in intestinal inflammation.
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